EULAR rheumatology open · 2026
In search of a window of opportunity in axial spondyloarthritis: treatment outcomes across different symptom durations.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Steimer Annik, Götschi Andrea, Ramiro Sofia, Nissen Michael J, Bürki Kristina, Andor Michael, Grosswiler Simon, Kyburz Diego, Möller Burkhard, Adler Sabine, Dan Diana, Brülhart Bletsas Laure, Förger Frauke, Distler Oliver, Micheroli Raphael, Ciurea Adrian
Аннотация
OBJECTIVES: This study aimed to determine the effectiveness of a first tumour necrosis factor inhibitor (TNFi) in patients with short and long symptom duration in axial spondyloarthritis (axSpA), using alternative cut-offs for back pain duration: ≤1 year as very early, >1 year, and ≤5 years as intermediate axSpA, and >5 years as late axSpA.
METHODS: A total of 1161 patients with axSpA from the Swiss Clinical Quality Management registry, who had data on the duration of back pain and initiated their first TNFi, were included. Patients were categorised as follows: very early axSpA (N = 138), intermediate axSpA (N = 329), and late axSpA (N = 694). Adjusted logistic regression models were used to compare the likelihood of achieving a low disease activity status (Axial Spondyloarthritis Disease Activity Score [ASDAS] <2.1) at 1 year, adjusting for age, sex, human leucocyte antigen-B27, educational level, body mass index, ASDAS, current smoking, and presence of inflammation on magnetic resonance imaging of the sacroiliac joints. Drug survival was analysed using multiple-adjusted Cox proportional hazards models. Missing data were addressed through multiple imputation by chained equations.
RESULTS: Higher disease activity parameters were found at baseline in very early axSpA. However, no significant differences were observed in treatment response or TNFi retention between very early and late axSpA (odds ratio for ASDAS < 2.1 response 0.99, 95% CI: 0.62-1.59 and hazard ratio for drug discontinuation 1.09, 95% CI: 0.87-1.37).
CONCLUSIONS: Based on this real-world observational data, no evidence was found to suggest a superior effectiveness of TNFi in patients with very early axSpA compared with those with late axSpA.
METHODS: A total of 1161 patients with axSpA from the Swiss Clinical Quality Management registry, who had data on the duration of back pain and initiated their first TNFi, were included. Patients were categorised as follows: very early axSpA (N = 138), intermediate axSpA (N = 329), and late axSpA (N = 694). Adjusted logistic regression models were used to compare the likelihood of achieving a low disease activity status (Axial Spondyloarthritis Disease Activity Score [ASDAS] <2.1) at 1 year, adjusting for age, sex, human leucocyte antigen-B27, educational level, body mass index, ASDAS, current smoking, and presence of inflammation on magnetic resonance imaging of the sacroiliac joints. Drug survival was analysed using multiple-adjusted Cox proportional hazards models. Missing data were addressed through multiple imputation by chained equations.
RESULTS: Higher disease activity parameters were found at baseline in very early axSpA. However, no significant differences were observed in treatment response or TNFi retention between very early and late axSpA (odds ratio for ASDAS < 2.1 response 0.99, 95% CI: 0.62-1.59 and hazard ratio for drug discontinuation 1.09, 95% CI: 0.87-1.37).
CONCLUSIONS: Based on this real-world observational data, no evidence was found to suggest a superior effectiveness of TNFi in patients with very early axSpA compared with those with late axSpA.